Understanding the premalignant potential of atypical hyperplasia through its natural history: A longitudinal cohort study

Lynn C. Hartmann, Derek C Radisky, Marlene H. Frost, Richard J. Santen, Robert A. Vierkant, Lorelle L. Benetti, Yaman Tarabishy, Karthik Ghosh, Daniel W Visscher, Amy C Degnim

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Atypical hyperplasia is a high-risk premalignant lesion of the breast, but its biology is poorly understood. Many believe that atypical ductal hyperplasia (ADH) is a direct precursor for low-grade ductal breast cancer, whereas atypical lobular hyperplasia (ALH) serves as a risk indicator. These assumptions underlie current clinical recommendations. We tested these assumptions by studying the characteristics of the breast cancers that develop in women with ADH or ALH. Using the Mayo Benign Breast Disease Cohort, we identified all women with ADH or ALH from 1967 to 2001 and f ollowed themfor later breast cancers, characterizing side of breast cancer versus side of atypia; time to breast cancer; type, histology, and grade of breast cancer, looking for patterns consistent with precursors versus risk indicators. A total of 698 women with atypical hyperplasia were followed a mean of 12.5 years; 143 developed breast cancer. For both ADH and ALH, there is a 2:1 ratio of ipsilateral to contralateral breast cancer. The ipsilateral predominance ismarked in the first 5 years, consistent with a precursor phenotype for both ADH and ALH. For both, there is a predominance of invasive ductal cancers with 69% of moderate or high grade. Twenty-five percent are node positive. Both ADH and ALH portend risk for ductal carcinoma in situ and invasive breast cancers, predominantly ductal, with two thirds moderate or high grade. The ipsilateral breast is at especially high risk for breast cancer in the first 5 years after atypia, with risk remaining elevated in both breasts long term. ADH and ALH behave similarly in terms of later breast cancer endpoints.

Original languageEnglish (US)
Pages (from-to)211-217
Number of pages7
JournalCancer Prevention Research
Volume7
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Natural History
Hyperplasia
Longitudinal Studies
Carcinoma, Intraductal, Noninfiltrating
Cohort Studies
Breast Neoplasms
Breast
Breast Diseases
Histology
Phenotype

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Understanding the premalignant potential of atypical hyperplasia through its natural history : A longitudinal cohort study. / Hartmann, Lynn C.; Radisky, Derek C; Frost, Marlene H.; Santen, Richard J.; Vierkant, Robert A.; Benetti, Lorelle L.; Tarabishy, Yaman; Ghosh, Karthik; Visscher, Daniel W; Degnim, Amy C.

In: Cancer Prevention Research, Vol. 7, No. 2, 02.2014, p. 211-217.

Research output: Contribution to journalArticle

Hartmann, Lynn C. ; Radisky, Derek C ; Frost, Marlene H. ; Santen, Richard J. ; Vierkant, Robert A. ; Benetti, Lorelle L. ; Tarabishy, Yaman ; Ghosh, Karthik ; Visscher, Daniel W ; Degnim, Amy C. / Understanding the premalignant potential of atypical hyperplasia through its natural history : A longitudinal cohort study. In: Cancer Prevention Research. 2014 ; Vol. 7, No. 2. pp. 211-217.
@article{96cc6df774b2478ea4ea5304ef3a3842,
title = "Understanding the premalignant potential of atypical hyperplasia through its natural history: A longitudinal cohort study",
abstract = "Atypical hyperplasia is a high-risk premalignant lesion of the breast, but its biology is poorly understood. Many believe that atypical ductal hyperplasia (ADH) is a direct precursor for low-grade ductal breast cancer, whereas atypical lobular hyperplasia (ALH) serves as a risk indicator. These assumptions underlie current clinical recommendations. We tested these assumptions by studying the characteristics of the breast cancers that develop in women with ADH or ALH. Using the Mayo Benign Breast Disease Cohort, we identified all women with ADH or ALH from 1967 to 2001 and f ollowed themfor later breast cancers, characterizing side of breast cancer versus side of atypia; time to breast cancer; type, histology, and grade of breast cancer, looking for patterns consistent with precursors versus risk indicators. A total of 698 women with atypical hyperplasia were followed a mean of 12.5 years; 143 developed breast cancer. For both ADH and ALH, there is a 2:1 ratio of ipsilateral to contralateral breast cancer. The ipsilateral predominance ismarked in the first 5 years, consistent with a precursor phenotype for both ADH and ALH. For both, there is a predominance of invasive ductal cancers with 69{\%} of moderate or high grade. Twenty-five percent are node positive. Both ADH and ALH portend risk for ductal carcinoma in situ and invasive breast cancers, predominantly ductal, with two thirds moderate or high grade. The ipsilateral breast is at especially high risk for breast cancer in the first 5 years after atypia, with risk remaining elevated in both breasts long term. ADH and ALH behave similarly in terms of later breast cancer endpoints.",
author = "Hartmann, {Lynn C.} and Radisky, {Derek C} and Frost, {Marlene H.} and Santen, {Richard J.} and Vierkant, {Robert A.} and Benetti, {Lorelle L.} and Yaman Tarabishy and Karthik Ghosh and Visscher, {Daniel W} and Degnim, {Amy C}",
year = "2014",
month = "2",
doi = "10.1158/1940-6207.CAPR-13-0222",
language = "English (US)",
volume = "7",
pages = "211--217",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Understanding the premalignant potential of atypical hyperplasia through its natural history

T2 - A longitudinal cohort study

AU - Hartmann, Lynn C.

AU - Radisky, Derek C

AU - Frost, Marlene H.

AU - Santen, Richard J.

AU - Vierkant, Robert A.

AU - Benetti, Lorelle L.

AU - Tarabishy, Yaman

AU - Ghosh, Karthik

AU - Visscher, Daniel W

AU - Degnim, Amy C

PY - 2014/2

Y1 - 2014/2

N2 - Atypical hyperplasia is a high-risk premalignant lesion of the breast, but its biology is poorly understood. Many believe that atypical ductal hyperplasia (ADH) is a direct precursor for low-grade ductal breast cancer, whereas atypical lobular hyperplasia (ALH) serves as a risk indicator. These assumptions underlie current clinical recommendations. We tested these assumptions by studying the characteristics of the breast cancers that develop in women with ADH or ALH. Using the Mayo Benign Breast Disease Cohort, we identified all women with ADH or ALH from 1967 to 2001 and f ollowed themfor later breast cancers, characterizing side of breast cancer versus side of atypia; time to breast cancer; type, histology, and grade of breast cancer, looking for patterns consistent with precursors versus risk indicators. A total of 698 women with atypical hyperplasia were followed a mean of 12.5 years; 143 developed breast cancer. For both ADH and ALH, there is a 2:1 ratio of ipsilateral to contralateral breast cancer. The ipsilateral predominance ismarked in the first 5 years, consistent with a precursor phenotype for both ADH and ALH. For both, there is a predominance of invasive ductal cancers with 69% of moderate or high grade. Twenty-five percent are node positive. Both ADH and ALH portend risk for ductal carcinoma in situ and invasive breast cancers, predominantly ductal, with two thirds moderate or high grade. The ipsilateral breast is at especially high risk for breast cancer in the first 5 years after atypia, with risk remaining elevated in both breasts long term. ADH and ALH behave similarly in terms of later breast cancer endpoints.

AB - Atypical hyperplasia is a high-risk premalignant lesion of the breast, but its biology is poorly understood. Many believe that atypical ductal hyperplasia (ADH) is a direct precursor for low-grade ductal breast cancer, whereas atypical lobular hyperplasia (ALH) serves as a risk indicator. These assumptions underlie current clinical recommendations. We tested these assumptions by studying the characteristics of the breast cancers that develop in women with ADH or ALH. Using the Mayo Benign Breast Disease Cohort, we identified all women with ADH or ALH from 1967 to 2001 and f ollowed themfor later breast cancers, characterizing side of breast cancer versus side of atypia; time to breast cancer; type, histology, and grade of breast cancer, looking for patterns consistent with precursors versus risk indicators. A total of 698 women with atypical hyperplasia were followed a mean of 12.5 years; 143 developed breast cancer. For both ADH and ALH, there is a 2:1 ratio of ipsilateral to contralateral breast cancer. The ipsilateral predominance ismarked in the first 5 years, consistent with a precursor phenotype for both ADH and ALH. For both, there is a predominance of invasive ductal cancers with 69% of moderate or high grade. Twenty-five percent are node positive. Both ADH and ALH portend risk for ductal carcinoma in situ and invasive breast cancers, predominantly ductal, with two thirds moderate or high grade. The ipsilateral breast is at especially high risk for breast cancer in the first 5 years after atypia, with risk remaining elevated in both breasts long term. ADH and ALH behave similarly in terms of later breast cancer endpoints.

UR - http://www.scopus.com/inward/record.url?scp=84893840408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893840408&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-13-0222

DO - 10.1158/1940-6207.CAPR-13-0222

M3 - Article

C2 - 24480577

AN - SCOPUS:84893840408

VL - 7

SP - 211

EP - 217

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 2

ER -